Evidence map›Paper›PMID 26969027›Full record

ArticleJournal of cellular and molecular medicine2016

Knockdown of cullin 4A inhibits growth and increases chemosensitivity in lung cancer cells.

Ming-Szu Hung, I-Chuan Chen, Liang You, David M Jablons, Ya-Chin Li, Jian-Hua Mao, Zhidong Xu, Jr-Hau Lung, Cheng-Ta Yang, Shih-Tung Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. CUL4The American journal of pathology · 2021
    Article
  7. Article
  8. Observational
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Ming-Szu HungDivision of Thoracic Oncology, Department of Pulmonary and Critical Care Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan.
I-Chuan ChenDepartment of Emergency Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan.
Liang YouThoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
David M JablonsThoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Ya-Chin LiDivision of Thoracic Oncology, Department of Pulmonary and Critical Care Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan.
Jian-Hua MaoLife Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
Zhidong XuThoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Jr-Hau LungDepartment of Medical Research and Development, Chang Gung Memorial Hospital, Chiayi, Taiwan.
Cheng-Ta YangDepartment of Respiratory Care, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Shih-Tung LiuDepartment of Microbiology and Immunology, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Chiayi Chang Gung Memorial Hospital · TWUCSF Helen Diller Family Comprehensive Cancer Center · USChang Gung Memorial Hospital · TWChang Gung University · TWLawrence Berkeley National Laboratory · USMemorial Hospital of South Bend · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cullin 4A (Cul4A) has been observed to be overexpressed in various cancers. In this study, the role of Cul4A in the growth and chemosensitivity in lung cancer cells were studied. We showed that Cul4A is overexpressed in lung cancer cells and tissues. Knockdown of the Cul4A expression by shRNA in lung cancer cells resulted in decreased cellular proliferation and growth in lung cancer cells. Increased sensitivity to gemcitabine, a chemotherapy drug, was also noted in those Cul4A knockdown lung cancer cells. Moreover, increased expression of p21, transforming growth factor (TGF)-β inducible early gene-1 (TIEG1) and TGF beta-induced (TGFBI) was observed in lung cancer cells after Cul4A knockdown, which may be partially related to increased chemosensitivity to gemcitabine. G0/G1 cell cycle arrest was also noted after Cul4A knockdown. Notably, decreased tumour growth and increased chemosensitivity to gemcitabine were also noted after Cul4A knockdown in lung cancer xenograft nude mice models. In summary, our study showed that targeting Cul4A with RNAi or other techniques may provide a possible insight to the development of lung cancer therapy in the future.

Indexed as

Gene Knockdown TechniquesAnimalsAntineoplastic AgentsBlotting, WesternCell Line, TumorCell ProliferationCullin ProteinsCyclin-Dependent Kinase Inhibitor p21DeoxycytidineFemaleGemcitabineHumansInhibitory Concentration 50Lung NeoplasmsMice, Inbred BALB CNeoplasm ProteinsAntineoplastic AgentsCUL4A protein, humanCullin ProteinsCyclin-Dependent Kinase Inhibitor p21DeoxycytidineGemcitabineNeoplasm ProteinsRNA, Small InterferingchemotherapyCul4Alung cancerp21

Identifiers

PMID26969027
PMCPMC4929302
OpenAlexW2296724554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.